Curon Medical's low stockholder equity falls foul of US stock market:
This article was originally published in Clinica
Curon Medical, the Fremont, California company focused on treatment of gastrointestinal disorders, is facing possible delisting from the US Nasdaq stock exchange. The firm's stockholder equity, as of the end of 2005, was $2.2m, falling short of the minimum $2.5m stipulated by Nasdaq to remain listed on the exchange. Curon, which has seen its share price trading below $1 for nearly a year, is now required to provide by February 22 a plan for regaining market compliance.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.